Пациенты Option Care, проходящие инфузионную иммуноглобулинотерапию на дому, добиваются лучших результатов с более низкими затратами
By: Option Care
November 12, 2015
SAN ANTONIO — Option Care patients treated with immunoglobulin (IG) therapy at home with a high level of clinical oversight had better outcomes compared to others receiving the therapy according to a first-of-its-kind study presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting this week. The researchers, who evaluated data from Option Care as compared to a large national database, also determined that the cost of therapy was lower. [*]Orange J, Kirkham H, Ayer G, et al. Improved clinical outcomes for patients receiving immunoglobulin therapy through specialty pharmacy or home infusion services. Paper presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2015 Annual Scientific Meeting: Nov 5-9, 2015; San Antonio.
One of the nation’s largest providers of home and alternate treatment site infusion services, Option Care provides high-quality, high-touch clinical support to patients undergoing treatment for complex conditions, including those receiving IG. Option Care’s unique treatment model combines locally delivered care with nationally managed treatment protocols and outcomes data collection. Specially trained infusion nurses and pharmacists provide individualized, expert IG treatment and patient education in the home. Patient-reported outcome measures — a scientific way of capturing patient experience — are collected by a dedicated team of IG experts and shared with patient’s broader health care team to keep everyone on the same page about the patient’s health status and to optimize the treatment plan.
“We conducted this research to test the hypothesis that patients who receive higher levels of clinical care in the home end up having better outcomes, ” said Jordan Orange, M.D., Ph.D., lead investigator of the study and professor of pediatrics and immunology at Baylor College of Medicine in Houston. “We found that the provision of comprehensive and consistent care in a patient’s own home does indeed lead to better outcomes. And an added benefit was that it was actually more cost effective.”
Иммуноглобулинотерапия назначается пациентам с нарушениями работы иммунной системы, например, иммунодефицитами или аутоиммунными заболеваниями, включая некоторые нервно-мышечные заболевания. Лечение может проводиться в стационаре клиники, в амбулаторном больничном инфузионном центре, в кабинете врача, в других центрах инфузионной терапии или на дому.
В ретроспективном исследовании за период с 1 августа 2011 г. по 30 июня 2014 г. д-р Орандж и его коллеги оценили результаты пациентов Option Care, получающих иммуноглобулинотерапию на дому, и сравнили их с контрольной группой, результаты которой зарегистрированы в крупной национальной базе данных административной отчетности IMS Pharmetrics Plus. Пациенты проходили иммуноглобулинотерапию одним из двух способов: внутривенно, с введением непосредственно в кровоток, и подкожно, с введением под первый слой кожи. Исследователи сравнили результаты каждого пациента Option Care с четырьмя пациентами из базы данных: всего 227 пациентов Option Care на внутривенной иммуноглобулинотерапии и 908 пациентов из контрольной группы; и 59 пациентов Option Care на подкожной иммуноглобулинотерапии и 236 пациентов из контрольной группы. Исследователи получили следующие результаты:
- Serious bacterial infections were lower in Option Care IVIG patients (.16 per patient per year) compared to control IVIG patients (.29 per patient per year)[*]Orange J, Kirkham H, Ayer G, et al. Improved clinical outcomes for patients receiving immunoglobulin therapy through specialty pharmacy or home infusion services. Paper presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2015 Annual Scientific Meeting: Nov 5-9, 2015; San Antonio.
- Serious adverse events (renal impairment, hepatitis, anaphylaxis and aseptic meningitis) were lower in Option Care SCIG patients (.08 per patient per year) compared to SCIG control patients (.34 per patient per year). [*]Orange J, Kirkham H, Ayer G, et al. Improved clinical outcomes for patients receiving immunoglobulin therapy through specialty pharmacy or home infusion services. Paper presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2015 Annual Scientific Meeting: Nov 5-9, 2015; San Antonio.
- Costs were lower overall for Option Care IVIG patients compared to controls ($112,756 vs. $120,567 per patient per year).[*]Orange J, Kirkham H, Ayer G, et al. Improved clinical outcomes for patients receiving immunoglobulin therapy through specialty pharmacy or home infusion services. Paper presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2015 Annual Scientific Meeting: Nov 5-9, 2015; San Antonio.
“Delivering high quality care for all of our patients is our top priority. We believe that our high-touch care model benefits patients, and we are pleased that this IG data bears that out,” said Paul Mastrapa, CEO of Option Care. “Not only do our patients appreciate the quality of life benefits of receiving care in the home, this research shows they also are getting the best quality care at a lower cost.”
Об Американском колледже аллергологии, астмы и иммунологии (ACAAI)
The ACAAI is a professional medical organization of more than 6,000 allergists-immunologists and allied health professionals, headquartered in Arlington Heights, Ill. The College fosters a culture of collaboration and congeniality in which its members work together and with others toward the common goals of patient care, education, advocacy and research. ACAAI allergists are board-certified physicians trained to diagnose allergies and asthma, administer immunotherapy, and provide patients with the best treatment outcomes. For more information and to find relief, visit www.AllergyandAsthmaRelief.org.
О компании Option Care
Option Care Enterprises, Inc., ранее Walgreens Infusion Services, Inc., предлагает высококачественный клинический уход, осуществляемый специально обученными медработниками, фармацевтами и диетологами, специализирующимися на инфузионной терапии, которые работают с пациентами с самыми разными острыми, хроническими и редкими заболеваниями. Являясь одним из крупнейших в стране поставщиков инфузионной терапии на дому и в альтернативных условиях лечения, Option Care имеет 92 аптечных пункта для проведения инфузионной терапии и 110 альтернативных пунктов лечения по всей стране. Узнайте больше на www.OptionCare.com.
# # #
Контактная информация для СМИ
Option Care
Lauren Kotarski
312-558-1770
LKotarski@pcipr.com
You might also be interested in:
Option Care Names Chief Financial Officer
DEERFIELD, Ill. — Option Care, an independent infusion services company, today announced the appointment of Michael H. Shapiro as Senior Vice President and Chief Financial Officer. Shapiro will lead all aspects of Option Care’s finance, accounting, treasury and M&A functions, working directly with Chief Executive Officer Paul Mastrapa as part of the Option Care executive […]
Новые результаты анализа данных Option Care подтверждают, что пациенты с сердечной недостаточностью, проходящие инотропную инфузионную терапию на дому в дополнение к правильно подобранной лекарственной терапии, имеют более высокий процент выживаемости
BANNOCKBURN, Ill., May 16, 2018 — Survival may improve when advanced heart failure patients receiving home infusion of inotropic therapy are also receiving guideline-directed care, suggest results of a large study recently published in The Journal of Heart and Lung Transplantation. The study was conducted by investigators from Keck School of Medicine of USC and Option […]